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Introduction: Idiopathic pulmonary fibrosis (IPF) is one of the most frequent interstitial lung
disease. Emphysema can be associated with IPF as described in the «Combined pulmonary
fibrosis and emphysema» syndrome.
Aim: The primary endpoint of this retrospective cohort study was to evaluate the impact of the
association of IPF and emphysema on lung function tests parameters (FVC, TLC, FEV1, FEV1/
FVC and DLCO). The secondary endpoint was to assess the impact of the associated radiological
emphysema on lung function parameters used in the du Bois prognostic score recently devel-
oped by Ron du Bois et al.
Method: We retrospectively reviewed the medical files of 98 patients with lung fibrosis who
were followed in our University Hospital with access to pharmacological studies and lung trans-
plantation from 1981 to 2011. Fifty six patients were considered for analysis. The collected
data included gender, age, smoking history and respiratory hospitalizations. We also analysed
their pulmonary functional parameters along with radiological characteristics, in particular the
presence of emphysema which was assessed on thoracic high resolution CT scan. The du Bois
score was retrospectively calculated from these data.
Results: TLC and FVC at diagnosis were significantly higher in the IPF-E group compared to the
IPF group (respectively 86.6  17.2% pv versus 72.0  15.0% pv; p: 0.004 and 86.8  18.4% pv
versus 72.6  20.6% pv; p: 0.020). The FVCt0 used in the calculation of the du Bois prognostic
score was significantly higher in the IPF-E group. By cons, FVCt6t0 was not statistically
different between the two groups.
Conclusion: Radiological emphysema associated with IPF had an impact on pulmonary function
tests. Despite this difference, the du Bois score was not statistically different between theseodinne, Avenue Dr G. Therasse 1, 5530 Yvoir, Belgium. Tel.: þ32 81423351; fax: þ32 81423352.
il.com (A. Bodlet).
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1782 A. Bodlet et al.two groups. Nevertheless, after one year of follow up, the patients with emphysema were in a
subclass with a lower mortality rate than those without emphysema.
ª 2013 Elsevier Ltd. All rights reserved.Figure 1 IPF associated with emphysema. a: In this case,
paraseptal emphysema is predominant at the apex. b: This is
the same patient as in Fig. 1a with emphysema predominant at
the apex and IPF at the bases. IPF is lateralized in the right
lung. Upper-lobe emphysema associated with lower-fibrosis is
typical from “Combined pulmonary fibrosis and emphysema
syndrome” (CPFE).Introduction
Idiopathic pulmonary fibrosis (IPF) is one of the most
frequent interstitial lung disease (ILD), histopathologically
associated with usual interstitial pneumonia (UIP) [1]. It is a
severe chronic disease of unknown aetiology, with a median
survival of 2e3 years after diagnosis. By the time of diag-
nosis, two thirds of patients are more than 60 years old [2].
Emphysema can be associated with IPF. Tobacco smoking
is a confounding factor, linked to these two respiratory
disorders [3,4]. The combined pulmonary fibrosis and
emphysema syndrome (CPFE) is a recently described entity
associating a lower lobe fibrosis and an upper-lobe
emphysema [5e7]. Certain authors consider this syndrome
as a disease per se and not as an accidental association of
IPF and emphysema. The impact of the presence of CPFE
syndrome on survival is still unclear [8,9].
The only intervention with a significantly positive impact
on survival in IPF is lung transplantation (LTx) [10]. The
treatment of gastro-oesophageal reflux has also been linked
with a significantly better survival [11]. The presence of
pulmonary hypertension is associated with a dismal prog-
nosis [12] as are greater age, male gender, lower FVC%
predicted and lower DLCO% predicted [13]. Lower peak
oxygen consumption during cardiopulmonary exercise
testing, oxygen desaturation during 6-min walking test
(6MWT) and lower 6-min-walk distance have also been
associated with a higher risk of death in IPF [13]. Higher
degrees of hypoxaemia occur in more advanced stages of
the disease but whether this can be considered as a prog-
nostic factor or not, is yet to be established [14e16].
Recently, du Bois et al. proposed a mortality risk scoring
system for patients with IPF [17]. This score was calculated
in a population including the patients from two different
studies where emphysema was not an exclusion criterion.
This score uses four predictors (risk factors) of mortality:
age, 24-week history of respiratory hospitalization (the first
24 weeks after the diagnosis of IPF), percent predicted FVC
at baseline and 24-week change in percent predicted FVC
(t6  t0). The calculated total risk score predicted the one
year probability of death. Among these risk factors of
mortality, the FVC was considered as an independent pre-
dictor of mortality [17].
The primary endpoint of our study was to provide pul-
monary function tests (PFTs) in an IPF population without
associated emphysema (IPF group) or with associated
emphysema (IPF-E group). The secondary endpoint was to
assess the impact of the associated radiological emphysema
on lung function parameters used in the recently proposed
du Bois prognostic score [17].
Methods
The medical files of 98 patients that had been diagnosed
with lung fibrosis between 1981 and 2011 in our universityhospital with access to pharmacological studies and lung
transplantation were retrospectively reviewed.
Lung function testing and medical imaging were sys-
tematically reviewed in all patients.
Other data that were collected included: the sex and the
age of the patients, a history of tobacco use (categorized as
smokers or non-smokers), surgical lung biopsy (SLB) results,
the presence of pulmonary arterial hypertension (PAH), the
bronchoalveolar lavage cell count values, a history of res-
piratory hospitalization, the IPF treatments and the causes
of death.
The diagnosis of IPF was retrospectively confirmed ac-
cording to consensus criteria of the American Thoracic So-
ciety (ATS), the European Respiratory Society (ERS), the
Japanese Respiratory Society (JRS) and the Latin-American
Thoracic Society (ALAT) guidelines (2011) [1].
Emphysema was diagnosed based on Schmidt et al.’s
HRCT scan criteria [14]. The type (centrilobular or para-
septal) and the location (apex, bases, diffuse or lateral-
ized) of the emphysema were also analysed. The
classification was validated by a radiologist (Figs. 1 and 2).
Figure 2 IPF without emphysema associated. This figure
shows some of the HRCT criteria for UIP pattern according to
the ATS/ERS/JRS/ALAT guidelines of 2011: the presence of
subpleural abnormalities, predominantly at the bases; the
presence of reticular abnormality and the presence of honey-
combing, with traction bronchiectasis in this case.
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according to centre-specific protocols. Before 2005, for
each measurement, three tests were performed and the
best value was taken into account. Therefore, the consid-
ered test was free of artefact. After 2005, spirometry tests
were performed according to ATS/ERS guidelines of 2005
[18]. Spirometry was used for the measurement of forced
vital capacity (FVC), forced expiratory volume in one sec-
ond (FEV1) and Tiffeneau index (FEV1/FVC). Total lung ca-
pacity (TLC) was determined by plethysmography. Diffusing
capacity of the lung for carbon monoxide (DLCO) mea-
surement was performed with various methods (single-
breath with helium-CO or CO-methane).
The data collected included FVC, FEV1, FEV1/FVC, TLC,
DLCO, loss of FVC at 6 months and loss of DLCO at 6 months.
The du Bois score was secondarily calculated with the
collected data.Table 1 Demographic characteristics and non-PFTs data at base
presented as absolute values and percentages into brackets. For “
arterial oxygen tension; t0: at baseline; PAH: pulmonary arterial














UK 24 (43)Statistical analysis
Descriptive statistics are presented as mean and standard
deviation (SD) with minimum and maximum values. Cate-
gorical and numerical variables were compared using the
chi-square and Wilcoxon rank sum tests respectively. All
tests were two-tailed. Statistical significance was set at
p < 0.05.
Statistical analysis was performed with the SPSS soft-
ware (SPSS Inc., Chicago, Ill.).
Results
Patients’ characteristics
Initially, the study cohort consisted of 98 patients with lung
fibrosis who had been treated in our centre between 1981
and 2011. Among these 98 patients, 25 patients were
excluded as the diagnosis of IPF could not be confirmed,
based on ATS/ERS/JRS/ALAT 2011 guidelines [1]. Six pa-
tients were excluded because there were no available PFT
values and eleven because no HRCT had been performed.
The cohort considered for analysis consisted of 56 patients
(Fig. 3). Patients’ characteristics are summarized in Table 1.
There were 44 men (79%) with a mean age at diagnosis of
65.5  10.8 years. There was no significant difference in
terms of age between the IPF-E group and the IPF group:
respectively 65.9  9.3 years and 65.3  11.8 years (p:
0.906). SLB had been performed in 17 patients (30%): 6
(29%) in IPF-E group and 11 (31%) in the IPF group.
Radiological emphysema was associated with IPF in 21
cases (38%). Emphysema was predominant in the lung apex
in thirteen patients (62%). It was basal in three patients
(14%), lateralized in one (5%) and diffuse in four (19%). The
basilar location is rather atypical. One patient had an
alpha1-antitrypsin (A1AT) deficiency, measured at 72 mg/dl
(normal range: 92 and 200 mg/dl), with a homozygous SS
phenotype. For the two other patients, the A1AT concen-
tration was not measured, but the alpha1-globulinline in the global population of 56 patients with IPF. Data are
paO2”, data are presented as mean  SD. UK: unknown; paO2:
hypertension; p: p value between IPF-E group and IPF group.
IPF-E group n (%) IPF group n (%) p
19 (90) 25 (71)
2 (10) 10 (29)
15 (72) 24 (69) NS (0.620)
3 (14) 7 (20)
3 (14) 4 (11)
6 (29) 11(31)
15 (71) 24 (69)
66.2  14.0 75.6  14.7 NS (0.179)
4 (19) 8 (23) NS (0.515)
9 (43) 11 (31)
8 (38) 16 (46)
Figure 3 Selection of patients suffering from IPF. ILD: interstitial lung disease; NSIP: non specific interstitial pneumonia; AIP:
acute interstitial pneumonia; CTD: connective tissue disease-associated lung disorders; IPF: idiopathic pulmonary fibrosis; PFT:
pulmonary function test; HRCT: high-resolution computed tomography; t0: at baseline.
a IPF at diagnosis between 1981 and 2011.
b IPF according to the ATS/ERS/JRS/ALAT guidelines (2011).
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level, the looking for an A1AT deficiency is not recom-
mended [19]. Eight patients (38%) had paraseptal emphy-
sema, nine (43%) had a centrilobular pattern and two (9.5%)
had a mixed type. The type of emphysema remained un-
determined in two cases (9.5%).
The majority of patients were current or former smokers
(39, 70%): 15 patients (72%) in the IPF-E group and 24 (69%)
in the IPF group (p: 0.620).
The presence of PAH, defined as an estimated systolic
pulmonary arterial pressure > 30 mmHg, had been evalu-
ated by transthoracic echocardiography during the initial
evaluation in 32 patients (13 patients with emphysema and
19 without emphysema). The occurrence of PAH in the 2
groups did not differ significantly (4 patients (19%) in the
IPF-E group versus 8 (23%) in the IPF group; p: 0.515).
The baseline and resting paO2 (ambient air) was
not significantly different between the two groups(66.2 mmHg  14.0 in the IPF-E population and
75.6 mmHg  14.7 in the IPF population; p: 0.179).Lung function testing at baseline
FVCt0 was 77.9%  20.8 predicted, TLCt0 was 77.7%  17.3
predicted, FEV1t0 was 79.3%  20.6 predicted, DLCOt0 was
51.0%  16.8 predicted and FEV1=FVCt0 was 81.0%  7.6.
At baseline, DLCO was performed in 49 patients using
various techniques: single-breath with helium-CO for 29
patients (59%), single-breath with CO-methane for 5 pa-
tients (10%) and undetermined method for 15 patients
(31%).
The presence of emphysema was associated with a
significantly higher value of TLC and FVC. In the IPF-E
group, TLC was 86.6%  17.2 predicted versus 72.0%  15.0
predicted in the IPF-group (p: 0.004). The FVC was higher in
Influence of radiological emphysema 1785IPF-E group compared to IPF-group: 86.8%  18.4 predicted
versus 72.6%  20.6 predicted (p: 0.020). The Tiffeneau
index (FEV1/FVC) was significantly lower in patients with
IPF-E (respectively 78.2%  7.4 versus 83.2%  7.2; p:
0.037). There was no significant difference in DLCO
(52.8%  16.8 predicted and 49.7%  16.9 predicted; p:
0.676) and in FEV1 (85.1%  20.6 predicted and
75.7%  20.0 predicted respectively; p: 0.057). Lung func-
tion tests at baseline are depicted in Table 2.
Lung function testing at 6 months
Globally, mean FVCt6 , ranging from 6 to 9 months, was
82.5%  20.6 predicted and mean FVCt6t0 was
0.9%  15.4 predicted. Results for DLCO at six months
were only available in 48 of the 56 patients. Mean DLCOt6
was 39.8%  13.8 predicted. The mean loss of percent
predicted DLCO after 6 months was 12.0%  15.0
predicted.
There was no significant difference between the two
groups regarding the loss of FVC at 6 months (1.24%  20.1
in the IPF-E population and 0.04%  11.4 in the IPF pop-
ulation; p: 0.593) as the loss of DLCO at 6 months
(11.0%  16.3 in the IPF-E population and 12.8%  14.4
in the IPF population; p: 0.857).
The second FEV1 ðFEV1tX Þ measurement had been taken
part at different moments (ranging from some months to
five years). It was significantly different between the two
populations (73.3%  19.7 predicted in the IPF-E group and
63.0%  17.9 predicted in the IPF group; p: 0.031). The loss
of FEV1 between t0 and tx ðFEV1tXt0Þ was not significantly
different (respectively 13.2%  20.7 predicted and
12.2%  15.1 predicted; p: 0.585).
Lung function tests at 6 months are depicted in Table 2.Table 2 Pulmonary function tests in 56 patients suffering from
presented as mean  SD. For “History of respiratory hospitaliza
brackets. *: Four predictors of mortality used in the du Bois score
total lung capacity; DLCO: diffusing capacity of the lung for carbon
at baseline; t6  t0: difference between 6 months and baseline; tx
IPF-E group and IPF group; NS: not significant; pv: predicted valu
IPF Whole population
N 56
Age t0 (years)* 65.5  10.8
History of respiratory hospitalization* 14 (25%)
FVCt0 (% pv)* 77.9  20.8
FVCt6t0 (%)* 0.86  15.4
Du Bois score 16.6  13.9
FEV1=FVCt0 (%) 81.0  7.6
TLCt0 (% pv) 77.7  17.3
FVCt6 (% pv) 82.5  20.6
DLCOt0 (% pv) 51.0  16.8
DLCOt6 (% pv) 39.8  13.8
DLCOt6t0 (%) 12.0  15.0
FEV1t0 (% pv) 79.3  20.6
FEV1tX (% pv) 73.3  19.7
FEV1tXt0 (%) 13.1  20.7The du Bois score
The du Bois score was not statistically different between
the two populations (14.6  14.0 in the IPF-E population
and 18.0  13.9 in the IPF population; p: 0.362). However,
patients without emphysema had a mean du Bois score of
18.0 corresponding to a 1-year probability of death of
5e10%. Although FVCt0 was markedly different, patients
with emphysema had a mean du Bois score of 14.6 corre-
sponding to a lower one-year death probability: between 2
and 5%. Fourteen patients (25%) had a 24-week history of
respiratory hospitalization: 5 among the patients suffering
from emphysema and 9 among the patients without
emphysema (p: 0.873).
The results of the du Bois score are reported in Table 2.
Therapies applied
Twenty-two patients received either N-acetylcysteine (NAC)
alone (17, 30%) or corticosteroids alone (5, 9%), with or
without oxygenotherapy. Six patients (11%) received corti-
costeroids associated with NAC, and 17 patients (30%)
received the same combination with or without azathioprine
or other treatments (e.g. cyclophosphamide, colchicine.).
Finally, 8 patients (14%) were included in IPF clinical trials
and the treatment was unspecified for 3 patients (5%).
Eight patients (14%) received a LTx including 4 patients
with a single LTx (7%) and 4 with a double LTx (7%). For 3
patients, the procedure was performed urgently.
Long term follow up
The follow-up period ranged from 6 months to 5 years.
Among the 56 patients, 9 patients were lost to follow upIPF associated or not with radiological emphysema. Data are
tion” data are provided as frequency with percentage into
. FVC: forced vital capacity; FEV1/FVC: Tiffeneau index; TLC:
monoxide; FEV1: forced expiratory volume in one second; t0:
: ranging from some months to five years; p: p value between
e.
IPF-E group IPF group p
21 35
65.9  9.3 65.3  11.8 NS (0.906)
5 (24%) 9 (26%) NS (0.873)
86.8  18.4 72.6  20.6 0.020
1.24  20.1 0.04  11.4 NS (0.593)
14.6  14.0 18.0  13.9 NS (0.362)
78.2  7.4 83.2  7.2 0.037
86.6  17.2 72.0  15.0 0.004
89.1  20.9 77.3  19.2
52.8  16.8 49.7  16.9 NS (0.676)
40.7  17.5 39.2  11.2
11.0  16.3 12.8  14.4 NS (0.857)
85.1  20.6 75.7  20.0 NS (0.057)
73.3  19.7 63.0  17.9 0.031
13.2  20.7 12.2  15.1 NS (0.585)
1786 A. Bodlet et al.and 2 patients died of unknown causes. Therefore, we
could not establish a link between IPF and death for these
eleven patients (20%). Causes of death were variable: acute
respiratory failure for seven patients (three sepsis, two
aspergillosis, one pneumothorax, one acutisation of IPF and
one tuberculosis), chronic respiratory failure due to the
evolution of IPF for four patients, brain lymphoma for one
patient and lung adenocarcinoma for one patient.Discussion
The purpose of this retrospective cohort was to evaluate
the impact of the association of IPF and radiological
emphysema (IPF-E) on lung function parameters (FVC, TLC,
FEV1, FEV1/FVC and DLCO). The secondary endpoint was to
assess the influence of this association on the du Bois score,
a new mortality risk scoring system for patients suffering
from IPF [17].
The IPF-E association is not a rare finding. In a recent
study, the prevalence of emphysema in an IPF cohort of 110
patients was high, estimated at 28% [20]. In our retro-
spective study, emphysema was found in 21 of 56 patients
(38%) diagnosed with IPF according to the last ATS/ERS
guidelines. Tobacco smoking is one of the most recognized
risk factors for the development of IPF [3] and emphysema
[4]. It was highly prevalent in our population as 70% of the
patients were current or former smokers with no statistical
difference between the IPF-E group and the IPF group (72%
and 69% respectively; p: 0.620). In the IPF-E population, the
location of emphysema was variable and mainly located at
the apex for 13 (62%) patients. Upper-lobe emphysema
associated with lower-fibrosis is typical of the CPFE syn-
drome described by Cottin et al., in 2005 [5]. As described
in the literature [5,8], there was a predominance of men in
our cohort (19, 90% in the IPF-E group and 25, 71% in the IPF
group). This gender has been reported as having a worse
prognosis [1].
In our study, TLCt0 and FVCt0 were significantly higher in
the IPF-E group compared to the IPF group (respectively,
86.6  17.2% pv versus 72.0  15.0% pv; p: 0.004 and
86.8  18.4% pv versus 72.6  20.6% pv; p: 0.020). These
results were similar to those of Cottin et al. [5] Indeed, in
their study, patients with CPFE had a characteristic func-
tional profile with preserved lung volume and an impaired
DLCO. DLCO was however more reduced than in our popu-
lation (<40% predicted). There was no comparison with IPF
data. Meija et al. [20] had quite different results. PFTs
were impaired without significant difference (between IPF-
E group and IPF group) but DLCO and TLC were not evalu-
ated. In our IPF-E cohort, the measurements of FVC and TLC
at baseline were normal due to an opposite effect of pul-
monary emphysema and fibrosis on volumes. Consequently,
in patients with a normal or subnormal spirometry, CPFE
may be underrecognised if DLCO is not measured [5].
DLCO is normally reduced in case of emphysema. DLCOt0
has also been considered as a reliable predictive value of
survival at baseline in patients with IPF [1] and has been
correlated to the percentage of predicted FVC with the
strongest correlation compared to other parameters
(measures of gas exchange, functional status, dyspnoea and
health-related quality of life) [21]. Moreover, changes inFVC (a parameter studied in the du Bois score, discussed
below) and DLCO are used in clinical practice to assess IPF
status and evolution [22]. In our study, percent-predicted
DLCO at baseline was severely reduced (51  16.8% pv)
but still above the threshold of severity of 40% pv described
by the recent ATS/ERS guidelines as a factor associated
with an increased mortality risk [1]. DLCOt0 was not sta-
tistically different between the two studied groups (IPF-E
52.8  16.8% pv versus IPF 49.7  16.9% pv; p: 0.676) as
well as the loss of DLCO after 6 months (respectively,
11.0  16.3% and 12.8  14.4% pv; p: 0.857). These
results were different from those of the recent study of
Ryerson et al. [8] In their study, patients with CPFE had also
less lung functional restriction but worse gas exchange
compared with IPF population and it was significant (p:
0.02). Fibrosis and emphysema had similar and additive
effects on DLCO.
In our study, FEV1t0 was mildly reduced in the IPF-E
group, without significant difference from the IPF group
(p: 0.057). The decline of FEV1, another factor with a
prognostic value [14,22], was also not statistically different
between the two populations (p: 0.585). This decline,
calculated on a period ranging from six months to five years
(a large period of time), reached more than 10% in the entire
population, the IPF-E group and the IPF group. In the study
of Schmidt et al., the longitudinal decline in FEV1 of 10% (at
6 or 12 months) was the strongest and most consistent pre-
dictor of mortality for patients with moderate-to-severe
emphysema on HRCT [14]. In population with none-to-mild
emphysema, a 10% relative decline in FVC (at 12 months)
or a 15% relative decline in DLCO (at 6 or 12 months) were
the best predictors of mortality. It is however difficult to
apply this approach to our population due to the retro-
spective design of our study (as described in the limitations).
Moreover, the FEV1 was not a parameter included in the du
Bois prognostic score calculated for our patients.
Tiffeneau index, FEV1=FVCt0 , which is not considered as
a mortality risk predictor, was lowered in the IPF-E group
but remained normal on average. In the whole population,
five patients had an associated obstructive respiratory
disorder (Tiffeneau index at baseline <70%). There was no
correlation between the Tiffeneau index and the score of
du Bois in the entire population and in both studied
subgroups.
Other factors that could be linked with a higher mor-
tality such as lower paO2 values or the presence of PAH
were not statistically different between the two groups at
baseline. Prior studies demonstrated that PAH had a sig-
nificant adverse impact on survival in patients suffering
from IPF associated or not with emphysema [12,23]. Con-
cerning the paO2, at rest as a predictor of mortality, there
were some contradictory results in the literature [14e16].
In our study, some recognized mortality risk factors as
mean age (relatively young in our population) and FVCt0
(mildly reduced in the IPF group) were comparable to what
was found in the population studied by du Bois et al. By
cons, the DLCOt0 was lower in the du Bois population but
not included in this score despite the predictive value of
this last parameter (as described above). In our population,
the du Bois score, calculated at baseline, was not statisti-
cally different between the two groups although they cor-
responded to different subclasses of 1-year mortality risk.
Influence of radiological emphysema 1787According to this score, patients with emphysema were at
lower risk of mortality, estimated at one year, than the
others: 2e5% at one year in the IPF-E group and 5e10% in
the IPF group. The evolution of lung function parameters in
these two groups was slow: FVC did not change significantly
between t0 and t6 in each group (IPF-E group FVCt0 :
86.8  18.4% pv, FVCt6 : 89.1  20.9% pv; IPF group FVCt0 :
72.6  20.6% pv, FVCt6 : 77.3  19.2% pv) and the loss of FVC
after 6 months, the most important parameter in the
calculation of the du Bois score, was not statistically
different between the two populations (IPF-E :
1.24  20.1% versus IPF: 0.04  11.4%; p: 0.593). In prior
studies, the FVC was considered as a responsive measure of
the clinical status in patients with IPF and a decline of 2%e
6% represented a small but clinically important difference
concerning the 1-year risk of death [21]. This could explain
why, in our population, the 1-year mortality risk according
to the du Bois score was not so high. The two other pa-
rameters remaining (24-week history of respiratory hospi-
talization and mean age t0) in this prognostic score were
also not statistically different between the two groups
(respectively: p 0.873 and p 0.906). Thus, FVCt0 was the
only parameter of the du Bois score which was statistically
different between the two groups. Our data suggest that du
Bois score should probably be used with caution in patients
with IPF associated with radiological emphysema.
According to this recently developed score, patients
with radiological emphysema were in another category of
mortality risk (with lower risk) than the IPF group. Ryerson
et al. [8], Jankowich et al. [24] and Akagi et al. [9] did not
observe a clear difference in survival between IPF-E group
and IPF group. In the study of Kurashima et al., survival was
better in patients with IPF-E compared with those with IPF
alone [25]. In contrary, different other studies demon-
strated that IPF-E patients had higher mortality rate
compared with those with IPF alone [12,20]. These results
reflect the difficulty to establish a prognostic score
including various parameters in a heterogeneous disease
with different stages of severity at diagnosis.
The proposed du Bois score was applied in an IPF pop-
ulation but was restricted to four selected factors. More-
over, the methodology used in our study limited the field of
our conclusions. In fact, our study had several limitations.
First, it was a study with a retrospective design. It was not
possible to establish causal links (between IPF and death
for example) and to compare the predicted mortality
calculated by the du Bois score to the actual observed
mortality (by survival curves for example). In addition,
many patients (16%) were lost to follow up and eight pa-
tients (14%) received a LTx which would have induced a
statistical bias if we had tried to establish mortality and
survival curves. Second, eligible patients were required to
have a SLB and/or a HRCT scan showing features consistent
with protocol-defined criteria according to the ATS/ERS/
JRS/ALAT guidelines recently published in 2011 [1]. Only 17
patients (30%) had a SLB but all of the included patients had
an HRCT. Third, different procedures used to perform PTFs
in several centres could interfere with the interpretations.
Furthermore, the method to measure DLCO was heteroge-
neous and unknown for 31% of patients. The FEV1tX in the
follow up covered a large period of time, which could
compromise the interpretation of the FEV1 evolution,particularly in current smokers. Fourth, there was a lack of
a quantitative radiographic scoring system to assess the
extent of emphysema and fibrosis in our subjects. Last, the
time-frame explored and defined by the score of du Bois is
short (only one year) to assess the impact of these func-
tional factors on prognosis. Moreover, this mortality risk
score was interpreted at one moment (at baseline in our
study). Therefore, the calculated score has been influenced
by IPF severity (PFTs and extent radiological abnormal-
ities). Consequently, despite the lack of significant differ-
ence in the du Bois score between the two selected
populations (probably due to the limitations described
above), extension of this score to a heterogeneous popu-
lation suffering from IPF is still questionable.
Conclusion
In summary, the association of radiological emphysema
with IPF has a significant impact on TLC and FVC at t0. TLC
and FVC at baseline are significantly higher in the emphy-
sema associated group than in the IPF group. By cons, in our
population with mild IPF, it does not seem to seriously in-
fluence one-year prognosis of patients suffering from IPF,
according to the du Bois prognostic score. Indeed, this
score was not statistically different between the two
groups, as well as FVCt6t0 , although they corresponded to
different subclasses of 1-year mortality risk.
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